Porous hernia repair stent with single transportation function as well as preparation method and application of porous hernia repair stent
By combining hydrophobic and water-absorbing nanofiber membranes on hernia repair stents and printing micron-scale drug-loading microspheres, the problem of surface flattening of traditional stents is solved, cell adhesion and growth is achieved, tissue repair effect is improved, and antibacterial drugs are used. Release reduces postoperative adhesions.
Patent Information
- Application Number
- CN202411089691.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-09
- Publication Date
- 2024-11-22
AI Technical Summary
The traditional hernia repair stent has a flat surface and lacks microstructure and pores, which limits cell adhesion and growth, affects tissue regeneration and repair effects.
Using a double-layer nanofiber membrane structure, the hydrophobic layer and the water-absorbing layer are combined to prepare nanofiber membranes by electrospinning, and micro-level drug-loading double-layer microspheres are printed on its surface to form a hiral hernia repair stent with a single transport function. The degradation of microspheres forms pores to promote cell growth.
Effective adhesion and growth of cells is achieved, tissue regeneration and repair effects are improved, and postoperative adhesion is reduced through the release of antibacterial drugs, providing a sterile environment, and promoting the growth and repair of new tissues.
Smart Images

Figure CN118987371A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the field of tissue engineering and medical repair technology, and in particular to a porous hernia repair stent with a unidirectional transport function and a preparation method and application thereof. Background Art
[0002] Abdominal wall hernia refers to the situation where organs or tissues in the abdominal cavity protrude beyond their normal position through weak points or defects in the abdominal wall. Its occurrence is related to factors such as congenital weakness of the abdominal wall, increased intra-abdominal pressure, pregnancy, obesity and aging. Treatment methods include observation, non-surgical means such as the use of hernia bands, and repair through traditional repair or laparoscopic surgery. The background of tension-free repair technology can be traced back to the 1980s, when traditional hernia repair methods faced challenges due to high recurrence rates and postoperative pain. In order to overcome these problems, surgeons began to use synthetic mesh instead of direct sutures to reduce the tension at the suture by covering the hernial orifice or weak points. In 1989, the tension-free repair method significantly reduced the recurrence rate and postoperative pain, and quickly gained widespread recognition. With the continuous improvement of technology and the optimization of synthetic mesh, tension-free repair technology has become the standard method for treating various types of hernias, which is of great significance for improving the quality of life of patients and accelerating postoperative recovery.
[0003] Postoperative adhesion after tension-free repair surgery refers to abnormal fibrous connections formed during the repair process of organ and tissue trauma caused by surgery. It is the most common complication after abdominal surgery. Postoperative adhesion often occurs at sites where tissues are squeezed, sutured or ligated. Therefore, a nanofiber membrane with tiny pores is used as a physical barrier to isolate the organs from the abdominal wall muscles. Nanofiber membranes made of hydrophobic materials are often used as an anti-adhesion layer for the abdominal wall, but when there is too much tissue fluid and blood in the early postoperative period, they will remain on the surface of the hydrophobic nanofiber membrane. Therefore, an anti-adhesion membrane with a unidirectional transport function composed of two different functions is proposed.
[0004] The surface of traditional patch stents is usually relatively flat and lacks microstructure and pores, which makes it impossible for cells to effectively adhere and grow on them, thus limiting their effectiveness in tissue regeneration and repair. Therefore, it is of great significance to develop a porous hernia repair stent with microstructure and pores that effectively promotes cell adhesion and growth and improves the effectiveness of tissue regeneration and repair processes and has a single transport function. Summary of the invention
[0005] In view of this, the present invention provides a porous hernia repair stent with a unidirectional transport function and a preparation method and application thereof, so as to solve the problem that the surface of a traditional patch stent is usually relatively flat and lacks microstructure and pores, which makes it impossible for cells to effectively adhere and grow thereon, thereby limiting its effect in the process of tissue regeneration and repair.
[0006] In order to achieve the above object, the present invention adopts the following technical solution:
[0007] The present invention provides a method for preparing a porous hernia repair stent with a unidirectional transport function, comprising the following steps:
[0008] (1) mixing polycaprolactone, dichloromethane and N,N-dimethylformamide to obtain a hydrophobic layer spinning solution A;
[0009] (2) electrospinning the hydrophobic layer spinning solution A to obtain a hydrophobic layer nanofiber membrane;
[0010] (3) mixing polyacrylonitrile, polycaprolactone, dichloromethane and N,N-dimethylformamide to obtain a water-absorbing layer spinning solution B;
[0011] (4) electrospinning the water-absorbing layer spinning solution B on the surface of the hydrophobic layer nanofiber membrane to obtain a double-layer nanofiber membrane composed of a water-absorbing layer and a hydrophobic layer;
[0012] (5) mixing epidermal growth factor and dichloromethane and then ultrasonically treating them to obtain an epidermal growth factor-dichloromethane solution; adding L-polylactic acid to the epidermal growth factor-dichloromethane solution and then ultrasonically treating them to obtain a core layer solution C of the drug-loaded double-layer microspheres;
[0013] (6) mixing levofloxacin and ethyl acetate and then ultrasonically treating them to obtain a levofloxacin-ethyl acetate solution; adding polylactic acid-glycolic acid to the levofloxacin-ethyl acetate solution and then ultrasonically treating them to obtain a shell solution D of drug-loaded double-layer microspheres;
[0014] (7) mixing the core layer solution C of the drug-loaded double-layer microspheres and the shell layer solution D of the drug-loaded double-layer microspheres by ultrasonic stirring to obtain a mixed solution;
[0015] (8) filtering the mixed solution and the polyvinyl alcohol solution, and freeze-drying the filter residue to obtain micrometer-sized drug-loaded double-layer microspheres;
[0016] (9) mixing polycaprolactone and micron-sized drug-loaded double-layer microspheres and heating them to obtain a polycaprolactone melt of drug-loaded double-layer microspheres; printing the polycaprolactone melt of drug-loaded double-layer microspheres on the surface of a double-layer nanofiber membrane composited with a water-absorbing layer and a hydrophobic layer by a 3D printer to obtain a composite scaffold;
[0017] (10) The composite stent is freeze-dried to obtain a porous hernia repair stent with a single transport function.
[0018] Preferably, in the step (1), the mass concentration of polycaprolactone in the hydrophobic layer spinning solution A is 12-18%; and the mass ratio of dichloromethane to N,N-dimethylformamide is 4-5:1.
[0019] Preferably, in steps (2) and (4), the electrospinning parameters are set as follows: the needle diameter is independently 23-24G, the voltage is independently 10-15kV, the collector receiving distance is independently 15-22cm, the liquid supply speed is independently 0.4-1.0mL / h, and the collection time is independently 5-7h.
[0020] Preferably, in step (3), the mass concentration of polyacrylonitrile in the water-absorbing layer spinning solution B is 10-17%, the mass concentration of polycaprolactone is 2-4%; and the mass ratio of dichloromethane to N,N-dimethylformamide is 4-5:1.
[0021] Preferably, the mass concentration of epidermal growth factor in the core layer solution C of the drug-loaded double-layer microspheres in step (5) is 2-5%, and the mass concentration of poly(lactic acid) is 20-25%; the mass concentration of levofloxacin in the shell layer solution D of the drug-loaded double-layer microspheres in step (6) is 10-15%, and the mass concentration of poly(lactic acid-glycolic acid) is 25-30%; in steps (5) and (6), the time of ultrasonic treatment is independently 80-250s.
[0022] Preferably, in step (7), the mass ratio of the core layer solution C of the drug-loaded double-layer microspheres to the shell layer solution D of the drug-loaded double-layer microspheres is 1:1-2; and the ultrasonic stirring and mixing time is 100-200 s.
[0023] Preferably, the mass concentration of polyvinyl alcohol in the mixed solution obtained by mixing the mixed solution and the polyvinyl alcohol solution in step (8) is 2 to 4%; in step (8), the mixing temperature is 20 to 25°C; the pore size of the filter used for filtration is 5 to 100 μm; the freeze-drying temperature is -60 to -30°C, and the freeze-drying time is 10 to 16 hours.
[0024] Preferably, in the step (9), the particle size of polycaprolactone is 1 to 2 mm; the mass ratio of polycaprolactone to micron-sized drug-loaded double-layer microspheres is 3 to 8:3; the heating temperature is 60 to 80°C, and the heating time is 500 to 800 s; the diameter of the needle used for printing is 0.5 to 1 mm, and the printing speed is 4 to 7 mm / s; in the step (10), the freeze-drying temperature is -60 to -30°C, and the freeze-drying time is 3 to 6 h.
[0025] The present invention also provides a porous hernia repair stent with a unidirectional transport function prepared by the method for preparing the porous hernia repair stent with a unidirectional transport function.
[0026] The present invention also provides the use of the porous hernia repair stent with unidirectional transport function in tension-free repair technology.
[0027] It can be seen from the above technical solution that compared with the prior art, the present invention has the following beneficial effects:
[0028] (1) The anti-adhesion layer in the present invention is formed by merging two layers of nanofiber membranes with different functions. The anti-adhesion layer is a dense nanofiber layer, which prevents the organs on the abdominal cavity side from adhering to the abdominal wall muscles through the pores of the stent. The hydrophobic layer close to the abdominal cavity side is made of hydrophobic material, and the surface is usually not easy to contact with water and form water droplets, which can effectively prevent the adhesion and attachment of cells, thereby reducing unnecessary cell growth and tissue formation. The water-absorbing layer close to the stent layer is made of a hydrophilic material, and its function is to absorb excess tissue fluid and blood around the patch, prevent nutrients from being transported to the inner side of the abdominal cavity, and prevent the formation of scar tissue and adhesion. The combined use of the water-absorbing layer and the hydrophobic layer can effectively prevent tissue fluid and blood from flowing back to the abdominal cavity after surgery, that is, prevent organ adhesion at the physical level, form a one-way transport function, cut off the transportation of nutrients and promote the growth of adhesion tissue.
[0029] (2) The micron-sized drug-loaded double-layer microspheres of the present invention are obtained by utilizing the incompatibility of solvents. The drug and the polymer carrier are first dissolved in two immiscible solvents respectively, and then made into an emulsion by mechanical oscillation or ultrasonic emulsification. The liquid dispersed into emulsion droplets is the inner dispersed phase, and the liquid dispersed in the emulsion droplets is the outer continuous phase. The inner dispersed phase solvent is then volatilized and removed under certain conditions, and the spherical material is precipitated and solidified into microspheres. The micron-sized drug-loaded double-layer microspheres of the present invention are loaded with antibacterial drugs and growth-promoting substances. During the degradation process, the antibacterial drugs are released in large quantities, providing a sterile environment for cells to grow. The growth-promoting substances in the nuclear layer are slowly released to promote cell growth.
[0030] (3) The stent layer of the present invention is composed of polycaprolactone and micron-sized drug-loaded double-layer microspheres, and the degradation rate of the micron-sized drug-loaded double-layer microspheres is faster than that of polycaprolactone. Micropores are generated during the degradation of the stent, releasing gaps to form a porous stent, providing adhesion space and migration channels for surrounding cells. This function can realize the dynamic generation of micropores, gradually improve the permeability of tissues and the nutrient supply of cells, and promote the growth and repair of new tissues. BRIEF DESCRIPTION OF THE DRAWINGS
[0031] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on the provided drawings without paying creative work.
[0032] Figure 1 Schematic diagram of the preparation process of the double-layer nanofiber membrane with a water-absorbing layer and a hydrophobic layer composite according to the present invention;
[0033] Figure 2 Schematic diagram of the preparation process of the micron-sized drug-loaded double-layer microspheres of the present invention;
[0034] Figure 3 This is a schematic diagram of the preparation process of the porous hernia repair stent with a single transport function according to the present invention;
[0035] Figure 4 This is a schematic diagram of the porous hernia repair stent with a unidirectional transport function described in the present invention when used in a tension-free repair technology. DETAILED DESCRIPTION
[0036] The present invention provides a method for preparing a porous hernia repair stent with a unidirectional transport function, comprising the following steps:
[0037] (1) polycaprolactone, dichloromethane and N,N-dimethylformamide are mixed and allowed to stand to obtain a hydrophobic layer spinning solution A;
[0038] (2) electrospinning the hydrophobic layer spinning solution A to obtain a hydrophobic layer nanofiber membrane;
[0039] (3) mixing polyacrylonitrile, polycaprolactone, dichloromethane and N,N-dimethylformamide to obtain a water-absorbing layer spinning solution B;
[0040] (4) electrospinning the water-absorbing layer spinning solution B on the surface of the hydrophobic layer nanofiber membrane to obtain a double-layer nanofiber membrane composed of a water-absorbing layer and a hydrophobic layer;
[0041] (5) mixing epidermal growth factor and dichloromethane and then ultrasonically treating them to obtain an epidermal growth factor-dichloromethane solution; adding L-polylactic acid to the epidermal growth factor-dichloromethane solution and then ultrasonically treating them to obtain a core layer solution C of the drug-loaded double-layer microspheres;
[0042] (6) mixing levofloxacin and ethyl acetate and then ultrasonically treating them to obtain a levofloxacin-ethyl acetate solution; adding polylactic acid-glycolic acid to the levofloxacin-ethyl acetate solution and then ultrasonically treating them to obtain a shell solution D of drug-loaded double-layer microspheres;
[0043] (7) mixing the core layer solution C of the drug-loaded double-layer microspheres and the shell layer solution D of the drug-loaded double-layer microspheres by ultrasonic stirring to obtain a mixed solution;
[0044] (8) filtering the mixed solution and the polyvinyl alcohol solution, and freeze-drying the filter residue to obtain micrometer-sized drug-loaded double-layer microspheres;
[0045] (9) mixing polycaprolactone and micron-sized drug-loaded double-layer microspheres and heating them to obtain a polycaprolactone melt of drug-loaded double-layer microspheres; printing the polycaprolactone melt of drug-loaded double-layer microspheres on the surface of a double-layer nanofiber membrane composited with a water-absorbing layer and a hydrophobic layer by a 3D printer to obtain a composite scaffold;
[0046] (10) The composite stent is freeze-dried to obtain a porous hernia repair stent with a single transport function.
[0047] In step (1) of the present invention, the mass concentration of polycaprolactone in the hydrophobic layer spinning solution A is preferably 12-18%, more preferably 13-17%, and more preferably 14-16%; the mass ratio of dichloromethane to N,N-dimethylformamide is preferably 4-5:1, and more preferably 4.5:1;
[0048] After mixing, the mixture is allowed to stand for preferably 0.5 to 1.5 hours, more preferably 1 hour, to eliminate bubbles;
[0049] After standing, stirring is performed. The stirring temperature is preferably 20-30°C, more preferably 25-28°C; the stirring speed is preferably 50-200 r / min, more preferably 100-150 r / min; the stirring time is preferably 1.5-2.5 h, more preferably 2 h.
[0050] The hydrophobic layer nanofiber membrane of the present invention is a polycaprolactone fiber membrane, which has a hydrophobic function and a contact angle of up to 120-130 degrees, and can transform the adhesion layer from hydrophilic to super-hydrophobic, preventing cells from climbing and proliferating on the scaffold, thereby achieving the anti-adhesion function.
[0051] In step (2) of the present invention, the electrospinning parameters are set as follows: the needle diameter is 23G, the voltage is 12-15 kV, the collector receiving distance is 15-18 cm, the liquid supply rate is 0.6-1.0 mL / h, and the collection time is 5-7 h.
[0052] In step (3) of the present invention, the mass concentration of polyacrylonitrile in the water-absorbing layer spinning solution B is preferably 10-17%, more preferably 12-16%, and more preferably 13-15%; the mass concentration of polycaprolactone is preferably 2-4%, more preferably 2.5-3.5%, and more preferably 3%; the mass ratio of dichloromethane to N,N-dimethylformamide is preferably 4-5:1, and more preferably 4.5:1;
[0053] After mixing, the mixture is allowed to stand for preferably 1 to 2 hours, more preferably 1.5 hours, in order to eliminate bubbles;
[0054] After standing, stirring is performed. The stirring temperature is preferably 20-30°C, more preferably 25-28°C; the stirring speed is preferably 50-200r / min, more preferably 100-150r / min; the stirring time is preferably 3.5-4.5h, more preferably 4h.
[0055] The water absorption function of the double-layer nanofiber membrane of the water-absorbing layer and the hydrophobic layer is achieved by the water absorption of polyacrylonitrile, and the addition of polycaprolactone enables better combination with the hydrophobic layer. At the same time, the one-way transport of tissue fluid and blood can be achieved, and the tissue fluid and blood can be prevented from seeping from the stent layer to the adhesion layer, thereby reducing the supply of nutrients to scar tissue and preventing organs from adhering to the stent.
[0056] In step (4) of the present invention, the electrospinning parameters are set as follows: the needle diameter is 24G, the voltage is 10-13 kV, the collector receiving distance is 18-22 cm, the liquid supply rate is 0.4-0.6 mL / h, and the collection time is 5-7 h.
[0057] The double-layer nanofiber membrane of the present invention, which is a composite of a water-absorbing layer and a hydrophobic layer, is a combination of two layers of nanofiber membranes with different functions, and can be used as a barrier for one-way transport, preventing tissue exudates and blood with nutrients from penetrating into the inner side of the abdominal cavity, and providing growth substances for adhesion tissues. The double-layer nanofiber membrane of the present invention has dense and narrow pores, which can prevent abdominal viscera from bridging to the pores of the stent and thus causing adhesion. The double-layer nanofiber membrane of the present invention has both hydrophobic and water-absorbing functions as an anti-adhesion layer. The combination of the two functions enables the double-layer nanofiber membrane to have a one-way transport function, that is, tissue fluid, blood and water can only be transmitted from the inner side of the abdominal cavity to the inner side of the abdominal cavity, and cannot enter the inner side of the abdominal cavity from the outer side of the abdominal cavity. This function can prevent postoperative exudates from providing nutrients for the formation of adhesion tissue of organs inside the abdominal cavity.
[0058] The mass concentration of epidermal growth factor in the core layer solution C of the drug-loaded double-layer microspheres in step (5) of the present invention is preferably 2-5%, more preferably 3-4%; the mass concentration of poly(L-lactic acid) is preferably 20-25%, more preferably 21-24%, and more preferably 22-23%.
[0059] In step (5) of the present invention, the mixing is sealed mixing; L-polylactic acid is added to the epidermal growth factor-dichloromethane solution, and the mixture is first sealed and allowed to stand and sealed and stirred in sequence, followed by ultrasonic treatment; the sealed standing time is preferably 0.5 to 1.5 hours, and more preferably 1 hour; the sealed stirring speed is preferably 50 to 200 r / min, and more preferably 100 to 150 r / min; the sealed stirring time is preferably 5 to 7 hours, and more preferably 6 to 6.5 hours.
[0060] In step (5) of the present invention, high-concentration L-polylactic acid will form inner-layer microspheres with larger diameters, while low-concentration L-polylactic acid will form a smaller number of microspheres.
[0061] The mass concentration of levofloxacin in the shell solution D of the drug-loaded double-layer microspheres in step (6) of the present invention is preferably 10-15%, more preferably 11-14%, and more preferably 12-13%; the mass concentration of polylactic acid-glycolic acid is preferably 25-30%, more preferably 26-29%, and more preferably 27-28%.
[0062] In step (6) of the present invention, the mixing is sealed mixing; polylactic acid-glycolic acid is added to the levofloxacin-ethyl acetate solution, and the mixture is first sealed and allowed to stand and sealed and stirred in sequence, followed by ultrasonic treatment; the sealed standing time is preferably 0.5 to 1.5 hours, more preferably 1 hour; the sealed stirring speed is preferably 50 to 200 r / min, more preferably 100 to 150 r / min; the sealed stirring time is preferably 5 to 7 hours, more preferably 6 to 6.5 hours.
[0063] In step (5) and step (6) of the present invention, the time of ultrasonic treatment is independently preferably 80 to 250 s, and more preferably 200 to 220 s.
[0064] In step (7) of the present invention, the mass ratio of the core layer solution C of the drug-loaded double-layer microspheres to the shell layer solution D of the drug-loaded double-layer microspheres is preferably 1:1-2, more preferably 1:1-1.5, and more preferably 1:1; the rotation speed of ultrasonic stirring and mixing is preferably 50-200 r / min, more preferably 100-150 r / min; the time of ultrasonic stirring and mixing is preferably 100-200 s, more preferably 120-180 s, and more preferably 130-160 s.
[0065] In the step (8) of the present invention, the mass concentration of polyvinyl alcohol in the mixed solution obtained by mixing the mixed solution and the polyvinyl alcohol solution is preferably 2-4%, more preferably 3%;
[0066] In the step (8), the mixing temperature is preferably 20 to 25°C, more preferably 21 to 24°C, and more preferably 22 to 23°C; the pore size of the filter used for filtration is preferably 5 to 100 μm, more preferably 10 to 80 μm, and more preferably 20 to 50 μm; the freeze-drying temperature is preferably -60 to -30°C, more preferably -50 to -40°C, and more preferably -40°C; the freeze-drying time is preferably 10 to 16 hours, and more preferably 12 to 14 hours.
[0067] In the present invention, the micron-sized drug-loaded double-layer microspheres utilize the property that L-polylactic acid is insoluble in ethyl acetate, and will spontaneously form semi-solid droplets dispersed in the polylactic acid-glycolic acid solution. Finally, the mixed solution is transferred to the external aqueous phase. As the solvent diffuses and evaporates, the L-polylactic acid at the core layer is first precipitated, and the outer layer of polylactic acid-glycolic acid is subsequently solidified to form a shell layer. The antibacterial drug carried by the shell layer is released in large quantities through the degradation of polylactic acid-glycolic acid, which has a rapid antibacterial effect after surgery. The growth-promoting substances carried by the core layer are slowly released as polylactic acid-glycolic acid and L-polylactic acid are successively degraded, achieving the effect of promoting cell reproduction and growth for a long time. As the micron-sized drug-loaded double-layer microspheres degrade, pores are slowly formed in the scaffold, realizing the dynamic generation of micropores, gradually improving the permeability of the tissue and the nutrient supply of the cells, providing adhesion and growth space for cell growth, and promoting the growth and repair of new tissues.
[0068] In step (9) of the present invention, the particle size of polycaprolactone is 1 to 2 mm; the particle size of the micron-sized drug-loaded double-layer microspheres is preferably 10 to 50 μm, more preferably 20 to 40 μm, and more preferably 30 μm; the mass ratio of polycaprolactone to micron-sized drug-loaded double-layer microspheres is preferably 3 to 8:3, more preferably 4 to 7:3, and more preferably 5 to 6:3; the ratio of the diameter of the micron-sized drug-loaded double-layer microspheres to the diameter of a single fiber of polycaprolactone is preferably 90 to 110:1, more preferably 95 to 105:1, and more preferably 100:1; This ratio can ensure that a single fiber of polycaprolactone contains enough micron-sized drug-loaded double-layer microspheres to achieve an antibacterial effect and form dense pores without affecting the mechanical properties of the stent; the heating temperature is preferably 60-80°C, and more preferably 70°C; the heating time is preferably 500-800s, and more preferably 600-700s, and more preferably 600s; the diameter of the needle used for printing is preferably 0.5-1mm, and more preferably 0.8mm; the printing speed is preferably 4-7mm / s, and more preferably 5-6mm / s.
[0069] In the present invention, the melting point and temperature stability of the micron-sized drug-loaded double-layer microspheres are both greater than 70°C, preventing decomposition and failure during the heating of polycaprolactone. The degradation rate of the micron-sized drug-loaded double-layer microspheres is greater than that of polycaprolactone, so that pores are formed on the polycaprolactone, forming space for cell adhesion and proliferation. The core layer and shell layer of the micron-sized drug-loaded double-layer microspheres in the present invention are respectively loaded with epidermal growth factor and levofloxacin drugs, and have antibacterial and growth-promoting functions. During the degradation process, the shell layer of the micron-sized drug-loaded double-layer microspheres will quickly release levofloxacin to achieve the effect of rapid sterilization. The core layer of the micron-sized drug-loaded double-layer microspheres is loaded with growth-promoting factors, and the double-layer structure can play a sustained-release role, achieving a long-term growth-promoting effect.
[0070] In the present invention, polycaprolactone as the main material of the stent can provide good mechanical properties, provide 16N / cm mechanical support, and prevent tearing when the force is too large. Polycaprolactone also has good biocompatibility, can effectively support cell attachment and growth, and meet the needs of tissue repair and regeneration.
[0071] In step (10) of the present invention, the freeze-drying temperature is preferably -60 to -30°C, more preferably -50 to -40°C, and more preferably -45°C; the freeze-drying time is preferably 3 to 6 hours, more preferably 4 to 5 hours, and more preferably 5 hours.
[0072] The present invention also provides a porous hernia repair stent with a unidirectional transport function prepared by the method for preparing the porous hernia repair stent with a unidirectional transport function.
[0073] The present invention also provides the use of the porous hernia repair stent with unidirectional transport function in tension-free repair technology.
[0074] The technical solutions provided by the present invention are described in detail below in conjunction with the embodiments, but they should not be construed as limiting the protection scope of the present invention.
[0075] Example 1
[0076] (1) 1.5 g of polycaprolactone was dissolved in dichloromethane and N,N-dimethylformamide (the mass ratio of dichloromethane to N,N-dimethylformamide was 4:1) at room temperature, allowed to stand for 1 h, placed on a magnetic stirrer, and stirred at 100 r / min at room temperature for 2 h to obtain a polycaprolactone solution with a mass concentration of 15%, which was the hydrophobic layer spinning solution A.
[0077] (2) Take 0.8 g of polyacrylonitrile and 0.2 g of polycaprolactone and dissolve them in dichloromethane and N,N-dimethylformamide (the mass ratio of dichloromethane to N,N-dimethylformamide is 4:1), let it stand for 2 hours, place it on a magnetic stirrer, and stir it at 100 r / min at room temperature for 4 hours to obtain a solution with a polyacrylonitrile mass concentration of 10% and a polycaprolactone mass concentration of 2.5%, which is the water-absorbing layer spinning solution B.
[0078] (3) The hydrophobic layer spinning solution A obtained in step (1) was injected into a 10 mL polypropylene syringe, allowed to stand for 1 h, and loaded into a spinning machine. A 23G caliber needle was selected, the high voltage power supply was set to 15 kV, the distance from the nozzle to the flat collector was 15 cm, the flow rate was 1.5 mL / h, and the electrospinning time was continued for 6 h to obtain a hydrophobic layer nanofiber membrane of a certain thickness.
[0079] (4) The water-absorbing layer spinning liquid B obtained in step (2) is injected into a 10 mL polypropylene syringe, allowed to stand for 1 h, and loaded into a spinning machine. A 24G caliber needle is selected, the high voltage power supply is set to 12 kV, the distance from the nozzle to the flat collector is 20 cm, the flow rate is 0.5 mL / h, and electrospinning is performed on the collector containing the hydrophobic layer nanofiber membrane in step (3) for 8 h to obtain a double-layer nanofiber membrane composed of a water-absorbing layer and a hydrophobic layer of a certain thickness.
[0080] (5) The double-layer nanofiber membrane collected in step (4) is removed from the flat plate, and the middle portion is cut out and dried for later use.
[0081] (6) 200 mg of epidermal growth factor was mixed in dichloromethane, sealed and ultrasonically treated for 200 seconds to obtain a dichloromethane solution containing epidermal growth factor; 2 g of L-polylactic acid was added to the dichloromethane solution containing epidermal growth factor, sealed and allowed to stand for 1 hour, and sealed and magnetically stirred for 6 hours (stirring speed was 100 r / min); the obtained epidermal growth factor-L-polylactic acid solution was ultrasonically treated for 80 seconds to obtain a uniformly dispersed epidermal growth factor-L-polylactic acid solution organic solution C.
[0082] (7) 80 mg of levofloxacin was poured into ethyl acetate, sealed and sonicated for 150 seconds to obtain an ethyl acetate solution containing levofloxacin; 2 g of polylactic acid-glycolic acid was added to the ethyl acetate solution containing levofloxacin, sealed and allowed to stand for 1 hour, and magnetically stirred for 6 hours (stirring speed was 100 r / min); the obtained levofloxacin-polylactic acid-glycolic acid solution was sonicated for 80 seconds to obtain a uniformly dispersed levofloxacin-polylactic acid-glycolic acid-ethyl acetate organic solution D.
[0083] (8) Add organic solution C to organic solution D, seal the mixture, and then ultrasonicate for 200 s to form semi-solid microspheres that are evenly dispersed.
[0084] (9) Add a 2% polyvinyl alcohol solution to the solution treated in step (8), seal the solution, and stir on a magnetic stirrer at room temperature for 2 h.
[0085] (10) The mixed solution prepared in step (9) was filtered through a 50 μm dialysis membrane, and the filtrate was filtered through a filter paper with a pore size of 10 μm. The filtered solid was collected, washed, and freeze-dried for 12 h to obtain drug-loaded double-layer microspheres with a diameter of 10 to 50 μm.
[0086] (11) 7 g of polycaprolactone powder and 3 g of drug-loaded double-layer microspheres are added to a barrel, and the barrel is heated to 70° C. The screw rotates to mix the powder into the barrel at 70° C. The polycaprolactone is heated and melted in the barrel. As the barrel rotates continuously, the drug-loaded double-layer microspheres are evenly distributed in the molten polycaprolactone, and a polycaprolactone melt mixed with drug-loaded double-layer microspheres is obtained, which is printed on the double-layer nanofiber membrane obtained in step (5) by a 3D printer to obtain a porous hernia repair stent with a single transport function.
[0087] Example 2
[0088] The difference from Example 1 is that the polyacrylonitrile in step (2) is omitted, and the mass ratio of dichloromethane to N,N-dimethylformamide in step (2) is adjusted to 3:1. The rest is the same as Example 1.
[0089] Example 3
[0090] The difference from Example 1 is that the step (11) of "adding 7 g of polycaprolactone powder and 3 g of drug-loaded double-layer microspheres into the barrel, heating the barrel to 70° C., and rotating the screw to mix the powder into the barrel at 70° C." is replaced with "adding 7 g of polycaprolactone powder and 200 mg of levofloxacin into the barrel, heating the barrel to 70° C., and rotating the screw to mix the powder into the barrel at 70° C.". The rest is the same as Example 1.
[0091] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. A method for preparing a porous hernia repair stent with a single transport function, characterized in that: The steps include: (1) mixing polycaprolactone, dichloromethane and N,N-dimethylformamide to obtain a hydrophobic layer spinning solution A; (2) electrospinning the hydrophobic layer spinning solution A to obtain a hydrophobic layer nanofiber membrane; (3) mixing polyacrylonitrile, polycaprolactone, dichloromethane and N,N-dimethylformamide to obtain a water-absorbing layer spinning solution B; (4) electrospinning the water-absorbing layer spinning solution B on the surface of the hydrophobic layer nanofiber membrane to obtain a double-layer nanofiber membrane composed of a water-absorbing layer and a hydrophobic layer; (5) mixing epidermal growth factor and dichloromethane and then ultrasonically treating them to obtain an epidermal growth factor-dichloromethane solution; adding L-polylactic acid to the epidermal growth factor-dichloromethane solution and then ultrasonically treating them to obtain a core layer solution C of the drug-loaded double-layer microspheres; (6) mixing levofloxacin and ethyl acetate and then ultrasonically treating them to obtain a levofloxacin-ethyl acetate solution; adding polylactic acid-glycolic acid to the levofloxacin-ethyl acetate solution and then ultrasonically treating them to obtain a shell solution D of drug-loaded double-layer microspheres; (7) mixing the core layer solution C of the drug-loaded double-layer microspheres and the shell layer solution D of the drug-loaded double-layer microspheres by ultrasonic stirring to obtain a mixed solution; (8) filtering the mixed solution and the polyvinyl alcohol solution, and freeze-drying the filter residue to obtain micrometer-sized drug-loaded double-layer microspheres; (9) mixing polycaprolactone and micron-sized drug-loaded double-layer microspheres and heating them to obtain a polycaprolactone melt of drug-loaded double-layer microspheres; printing the polycaprolactone melt of drug-loaded double-layer microspheres on the surface of a double-layer nanofiber membrane composited with a water-absorbing layer and a hydrophobic layer by a 3D printer to obtain a composite scaffold; (10) The composite stent is freeze-dried to obtain a porous hernia repair stent with a single transport function.
2. The method for preparing the porous hernia repair stent with a unidirectional transport function according to claim 1, characterized in that: In the step (1), the mass concentration of polycaprolactone in the hydrophobic layer spinning solution A is 12-18%; the mass ratio of dichloromethane to N,N-dimethylformamide is 4-5:
1.
3. The method for preparing the porous hernia repair stent with unidirectional transport function according to claim 1 or 2, characterized in that: In the steps (2) and (4), the electrospinning parameters are set as follows: the needle diameter is independently 23-24G, the voltage is independently 10-15kV, the collector receiving distance is independently 15-22cm, the liquid supply speed is independently 0.4-1.0mL / h, and the collection time is independently 5-7h.
4. The method for preparing the porous hernia repair stent with a unidirectional transport function according to claim 3, characterized in that: In the step (3), the mass concentration of polyacrylonitrile in the water-absorbing layer spinning solution B is 10-17%, the mass concentration of polycaprolactone is 2-4%, and the mass ratio of dichloromethane to N,N-dimethylformamide is 4-5:
1.
5. The method for preparing the porous hernia repair stent with unidirectional transport function according to claim 1, 2 or 4, characterized in that: The mass concentration of epidermal growth factor in the core layer solution C of the drug-loaded double-layer microspheres in step (5) is 2-5%, and the mass concentration of poly(lactic acid) is 20-25%; the mass concentration of levofloxacin in the shell layer solution D of the drug-loaded double-layer microspheres in step (6) is 10-15%, and the mass concentration of poly(lactic acid-glycolic acid) is 25-30%; in steps (5) and (6), the time of ultrasonic treatment is independently 80-250s.
6. The method for preparing the porous hernia repair stent with a unidirectional transport function according to claim 5, characterized in that: In the step (7), the mass ratio of the core layer solution C of the drug-loaded double-layer microspheres to the shell layer solution D of the drug-loaded double-layer microspheres is 1:1-2; and the ultrasonic stirring and mixing time is 100-200 seconds.
7. The method for preparing the porous hernia repair stent with a unidirectional transport function according to claim 6, characterized in that: The mass concentration of polyvinyl alcohol in the mixed solution obtained by mixing the mixed solution and the polyvinyl alcohol solution in step (8) is 2 to 4%. In step (8), the mixing temperature is 20 to 25°C; the pore size of the filter used for filtration is 5 to 100 μm; the freeze-drying temperature is -60 to -30°C, and the freeze-drying time is 10 to 16 hours.
8. The method for preparing the porous hernia repair stent with unidirectional transport function according to claim 6 or 7, characterized in that: In the step (9), the particle size of polycaprolactone is 1 to 2 mm; the mass ratio of polycaprolactone to micron-sized drug-loaded double-layer microspheres is 3 to 8:3; the heating temperature is 60 to 80° C., and the heating time is 500 to 800 s; the diameter of the needle used for printing is 0.5 to 1 mm, and the printing speed is 4 to 7 mm / s; in the step (10), the freeze-drying temperature is -60 to -30° C., and the freeze-drying time is 3 to 6 h.
9. A porous hernia repair stent with a single transport function prepared by the method for preparing a porous hernia repair stent with a single transport function according to any one of claims 1 to 8.
10. Use of the porous hernia repair stent with unidirectional transport function as claimed in claim 9 in tension-free repair technology.
